Published:
Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
ST. LOUIS, Aug. 19 /PRNewswire-FirstCall/ -- Sigma-Aldrich
(Nasdaq: SIAL) today announced the addition of over 2,000 antibodies to
its line of Prestige Antibodies(TM). These antibodies are developed by
the Human Proteome Resource and are commercially available through an
exclusive partnership with Sigma-Aldrich and Atlas Antibodies. As part of
a keynote HUPO 2008 Conference lecture given by Mathias Uhlen, Professor
of Microbiology, Royal Institute of Technology (KTH) inStockholm, Sweden,
the new antibodies were announced as the latest additions to the Human
Protein Atlas portal. Initially consisting of 1,800 antibodies, the
portfolio has grown to over 3,800 antibodies directed against 3,600 genes.
The goal of this project is to produce several thousand antibodies per
year and at least one antibody to all 22,000 non-redundant human proteins
by 2015. This latest batch of antibodies will be available inEurope
immediately and is expected to be available September 1st inthe United
States and in other international markets.
"The expansion of the Human Protein Atlas dramatically advances
Sigma-Aldrich's antibody offerings," said Dr. David Smoller, President of
Sigma-Aldrich's Research Biotech Business Unit. "By providing high
quality, highly-validated antibodies, we are addressing one of the largest
obstacles faced by the proteomics and cell biology research communities."
Prestige Antibodies are highly validated for specificity and are
designed to have low cross-reactivity to other human proteins. Each
Prestige antibody is accompanied by 576 tissue immunohistochemistry (IHC)
images and 118 cell and cell line immunocytochemistry (ICC) images. These
images, as well as immunofluorescence (IF) and western blotting (WB) data,
are publicly accessible via the Human Protein Atlas
(http://www.proteinatlas.org). Prestige Antibodies are optimized on a
single protocol and are tailored for high throughput operations, providing
the potential for significant time and cost savings for researchers.
Sigma-Aldrich is committed to building antibody content for life
science researchers through collaborations and an appreciable expansion of
its internal antibody production. Earlier this year, the company
announced a partnership with AbD Serotec, a Division of MorphoSys, to
design, produce and distribute unique recombinant research antibodies
using MorphoSys's proprietary HuCAL GOLD technology. Sigma-Aldrich
recently entered into a five-year collaboration with the University of
California, San Francisco, (UCSF) to develop optimal cell lines for the
production of monoclonal antibodies.
Prestige Antibodies(TM) are available at
http://www.sigma.com/prestige, where customers can search or browse for
available antibodies by specific gene name and ID, or by keywords.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company. Its biochemical and organic chemical products and kits
are used in scientific and genomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in
pharmaceutical and other high technology manufacturing. The Company has
customers in life science companies, university and government
institutions, hospitals, and in industry. Over one million scientists and
technologists use its products. Sigma-Aldrich operates in 36 countries and
has 8,000 employees providing excellent service worldwide. Sigma-Aldrich
is committed to Accelerating Customer Success through Leadership in Life
Science, High Technology and Service. For more information about
Sigma-Aldrich, please visit its award-winning website at
http://www.sigma-aldrich.com.
About Atlas Antibodies: Atlas Antibodies was founded in 2006 by
researchers at the Royal Institute of Technology (KTH) inStockholm and
the Rudbeck Laboratory, Uppsala University in Uppsala,Sweden. Atlas
Antibodies will handle the production, marketing and sales of the antibody
products developed and validated in the Human Proteome Resource (HPR)
Center. The Human Proteome Resource (HPR) Center is performing a
systematic exploration of the human proteome with Affinity (Antibody)
based Proteomics, combining high-throughput generation of
affinity-purified (mono-specific) antibodies with protein profiling using
tissue microarrays. The Human Proteome Resource (HPR) Center is located in
Stockholm and Uppsala,Sweden and is running the Swedish Human Protein
Atlas (HPA) program. The HPA program generates expression and localization
patterns of proteins in a large portion of both normal and cancer human
tissues and organs resulting in the antibody-based profiling presented in
the publicly available Human Protein Atlas (HPA)
(http://www.proteinatlas.org). The HPA vision is to enable the systematic
generation of quality assured antibodies to all non-redundant human
proteins and to use these reagents to functionally explore human proteins,
protein variants and protein interactions.
Cautionary Statement: This release contains forward-looking statements
relating to future performance, goals, strategic actions and initiatives
and similar intentions and beliefs and other statements regarding the
Companies' expectations, goals, beliefs, intentions and the like, which
involve assumptions regarding the Companies' operations and conditions in
the markets the Companies serve. The Companies do not undertake any
obligation to update these forward-looking statements.
SOURCE Sigma-Aldrich
Copyright © 2009, PRNewswire
newsblaze
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,MTC,HEA,BIO,CHM,JVN,PDT,TDS,MO-SIAL-Atlas-Antibds
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
